Abstracts Archive - Page 925 of 2607 - ACR Meeting Abstracts

Abstract Number: 1329 • ACR Convergence 2020
Subclinical Atherosclerosis Risk in Psoriatic Arthritis: Could It Be Prevented?
Mai Farouk¹, Salwa Moussa¹ and Rowaida Abdou¹, ¹Rhuematology Ain Shams University Hospitals, Cairo, Egypt
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthritis associated with psoriasis that can cause remarkable joint damage (1). Subclinical cardiovascular disease (CVD) due to…
Abstract Number: 1330 • ACR Convergence 2020
Subclinical atherosclertoic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study with 806 patients.
Inigo Gonzalez-Mazon¹, Javier Rueda-Gotor², Ivan Ferraz-Amaro³, Lara Sanchez-Bilbao⁴, David Martinez-Lopez⁵, Fernanda Genre⁶, Natalia Palmou Fontana⁷, Vanesa Calvo-Río², Sara Remuzgo-Martínez⁶, Veronica Pulito-Cueto⁶, Alfonso Corrales⁸, Leticia Lera-Gómez⁶, Virginia Portilla⁶, Cristina Mata⁹, Vanesa Hernández-Hernández¹⁰, Santos Castañeda¹¹, Esther Francisca Vicente-Rabaneda¹², C Fernandez-Carballido¹³, M Paz Martínez-Vidal¹⁴, David Castro-Corredor¹⁵, Joaquín Anino-Fernández¹⁵, Juan Carlos Quevedo-Abeledo¹⁶, Carlos Rodríguez-Lozano¹⁷, María Luz García Vivar,¹⁸, Eva Galínez-Agirregoikoa¹⁸, C. Fernandez-Diaz¹⁹, Javier Llorca²⁰, Raquel López-Mejías⁶, Esther Montes-Perez²¹, Diana Peiteado²², Chamaida Plasencia²³, Alejandro Balsa-Criado²⁴, Nuria Barbarroja²⁵, Lourdes Ladehesa-Pineda²⁶, Rafaela Ortega-Castro²⁷, Eduardo Collantes-Estévez²⁶, Ricardo Blanco²⁸ and Miguel Ángel González-Gay²⁹, ¹Hospital Universitario Marques de Valdecilla, Bezana, Spain, ²H.U. Marques de Valdecilla, Santander, Spain, ³Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁶Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁷UNIVERSITARY HOSPITAL MARQUES VALDECILLA, Santander, Spain, ⁸Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Hospital de Laredo, Santander, Spain, ¹⁰Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹¹Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ¹²Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ¹³H San Juan, Alicante, Spain, ¹⁴Hospital General Universitario de Alicante, Alicante, Spain, ¹⁵Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹⁶Hospital Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁷Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁸Hospital Universitario Basurto, Bilbao, Spain, ¹⁹H. Marqués de Valdecilla, Madrid, Spain, ²⁰School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ²¹Diagnóstico Médico Cantabria (DMC), Santander, Spain, ²²Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ²³Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ²⁴HOSPITAL UNIVERSITARIO LA PAZ, madrid, Spain, ²⁵Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²⁶Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ²⁷Hospital Universitario Reina Sofía, Córdoba, Spain, ²⁸Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ²⁹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Cardiovascular (CV) mortality and morbidity is increased in ankylosing spondylitits (AS) as compared to the general population. Carotid plaque, considered as a surrogate marker…
Abstract Number: 1331 • ACR Convergence 2020
Carotid Ultrasound Findings in Psoriatic Arthritis: A Case-control Study
Dionicio Ángel Galarza-Delgado¹, José Ramón Azpiri López², Iris Jazmín Colunga Pedraza³, Diana Elsa Flores Alvarado⁴, Octavio Ilizaliturri Guerra⁴, Paola Fernanda Frausto Lerma³, Itzel Corina Zárate Salinas², Alejandra Pérez Villar³, Mayra Alejandra Reyes Soto³, Salvador Lugo Pérez² and Andrea Cecilia Garza Acosta⁵, ¹Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Cardiology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, ³Rheumatology service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico, ⁵Radiology Service, Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Patients with psoriatic arthritis (PsA) have an increased risk of cardiovascular disease (CVD). The carotid ultrasound, which measures both carotid intima-media thickness (cIMT) and…
Abstract Number: 1332 • ACR Convergence 2020
Identifying the as Patient at Risk: Is Aortic Root Diameter Associated with HLA-B27?
Milad Baniaamam¹, Sjoerd C. Heslinga², M. Louis Handoko³, Thelma C. Konings³, Otto Kamp³, Vokko P. van Halm⁴, J. Christiaan van Denderen¹, Irene van der Horst-Bruinsma² and Mike Nurmohamed⁵, ¹Reade, Amsterdam, Netherlands, ²Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ³Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ⁴Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, ⁵Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory joint disease (IJD) associated with cardiac involvement particularly aortic valve regurgitation (AVR). AVR in AS is caused by…
Abstract Number: 1333 • ACR Convergence 2020
Ankylosing Spondylitis Patients at Risk of Developing Aortic Valve Regurgitation, Need for Mandatory Echocardiography?
Milad Baniaamam¹, Sjoerd C. Heslinga², Laura Boekel¹, M. Louis Handoko³, Thelma C. Konings³, Otto Kamp³, Vokko P. van Halm⁴, J. Christiaan van Denderen¹, Irene van der Horst-Bruinsma² and Mike Nurmohamed⁵, ¹Reade, Amsterdam, Netherlands, ²Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ³Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ⁴Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, ⁵Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands
Background/Purpose: The overall mortality rate in ankylosing spondylitis (AS) patients is increased by 60–90% compared with the general population. This higher mortality rate is predominately…
Abstract Number: 1334 • ACR Convergence 2020
Does Interstitial Lung Disease Represent a Real Comorbidity in Spondyloarthritis Patients? Results from an Ultrasound, Monocentric, Pilot Study
Andrea Delle Sedie¹, Emanuele Calabresi¹, Ilaria Romagnoli¹, Linda Carli² and Marta Mosca², ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Background: Interstitial lung disease (ILD) is a frequent complication in rheumatoid arthritis (RA) where it represents the most common extra-articular involvement (with a prevalence…
Abstract Number: 1335 • ACR Convergence 2020
Smoking, but Not Use of Complementary and Alternative Medicine Predicts Residual Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Dominic Seet¹, Li Wearn Koh², Preeti Dhanasekaran³, Man Hua Aw⁴, Rosa Lim Mui San², Siaw Ing Yeo⁴ and Manjari Lahiri¹, ¹National University Hospital, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³National University of Singapore, Singapore, Singapore, ⁴Singapore General Hospital, Singapore, Singapore
Background/Purpose: To describe the demographic and clinical characteristics of patients with inflammatory arthritis (IA) initiating biologic disease modifying anti-rheumatic drugs (bDMARD) who use complementary and…
Abstract Number: 1336 • ACR Convergence 2020
Bone Mineral Density, Trabecular Bone Score and Proximal Femur 3D-DXA Analysis in Psoriatic Diseases
Eric Toussirot¹, Renaud Winzenrieth², Maxime Desmarets³, Daniel Wendling⁴, Francois Aubin⁵ and Gilles Dumoulin⁶, ¹CIC biotherapies, Besançon University Hospital, Besançon, France, ²GALGO medical, Barcelona, Spain, ³INSERM CIC-1431, Besancon, France, ⁴CHU Besançon, department of rheumatology, Besancon, France, ⁵Dermatology, Besancon, France, ⁶Laboratoire de Biochimie Médicale, UF de Biochimie Endocrinienne et Métabolique, Besancon, France
Background/Purpose: current data regarding areal bone mineral density (aBMD) in patients with psoriasis (PsO) or psoriatic arthritis (PsA) are conflicting. Results on Trabecular Bone Score…
Abstract Number: 1337 • ACR Convergence 2020
Relationship of the Pro12Ala Polymorphism of the PPARg Gene with Inflammatory Activity, Osteoporosis and Obesity in Patients with Psoriatic Arthritis
Olga Compán¹, Maria Elisa Acosta², Sonia Pastor², Guadalupe Manzano Canabal², Luis Gomez-Lechon Quiros³, Cristina Hidalgo Calleja⁴, Noelia Cubino², Ricardo Usategui⁵, Rogelio Gonzalez Sarmiento⁵, Olga Martinez Gonzalez⁶, Ana Isabel Turrión², Javier Del Pino-Montes² and Carlos Montilla Morales², ¹Hospital Universitario de Salamanca, ´Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ⁴Hospital Universitario Salamanca, Salamanca, Spain, ⁵Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain, ⁶Hospital Universitario de Salamanca, Zamora, Spain
Background/Purpose: In the pathogenesis of psoriatic arthritis (PsA), increased inflammatory cytokines lead to increased RANGO-L activity and stimulation of osteoclasts, leading to osteoporosis. This comorbidity,…
Abstract Number: 1338 • ACR Convergence 2020
Identification of Muscle Associated Key Genes to Support Axial Spondyloarthritis Diagnosis by Transcriptomic Approach, the MyoSpA Study
Atlas Mashayekhi Sardoo¹, Daniel Sobral², Lucia Domingues³, Santiago Rodrigues-Manica⁴, Rita Pinheiro Torres⁴, Agna Neto⁵, Ana Filipa Fernandes⁶, Patricia Alves⁷, Julia Costa⁶, Ana Rita Grosso², Celso Cunha⁸, Jaime Branco⁹ and Fernando M Pimentel-Santos⁴, ¹3. CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ²Faculty of Science and Technology, Universidade Nova de Lisboa, Caparica, Portugal, ³NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal, ⁴CHLO, Hospital Egas Moniz, Lisbon, Portugal, ⁵1. Rheumatology Department, Hospital Central do Funchal, Madeira, Portugal. 2. Hospital de Egas Moniz, CHLO, Lisbon, Portugal. 3. CEDOC, NOVA Medical School, Lisbon, Portugal, Lisbon, Portugal, ⁶ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Oeiras, Portugal, ⁷IBET - Institute of Experimental Biology and Technology, Oeiras, Portugal, ⁸Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa, Lisbon, Portugal, ⁹2. Hospital de Egas Moniz, CHLO, Lisbon, Portugal. 3. CEDOC, NOVA Medical School, Lisbon, Portugal, Lisbon, Portugal
Background/Purpose: Early diagnosis of axial Spondyloarthritis (axSpA) represents a major clinical challenge nowadays. Increasing evidence has determined that early diagnosis, prompt treatment initiation and early…
Abstract Number: 1339 • ACR Convergence 2020
COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Rebecca Haberman¹, Rochelle Castillo¹, Alan Chen², Di Yan¹, Deborah Ramirez², Vaish Sekar², Robert Lesser², Gary Solomon², Andrea Neimann², Rebecca Blank¹, Peter Izmirly³, Dan Webster⁴, Alexis Ogdie⁵, Andrea Troxel², Samrachana Adhikari² and Jose Scher¹, ¹NYU School of Medicine, New York City, ²NYU Langone Health, New York City, ³New York University, New York, NY, ⁴Sage Bionetworks, Seattle, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The COVID-19 pandemic has quickly emerged as the most challenging global health crisis in a generation. Affecting initially China, New York City (NYC) quickly…
Abstract Number: 1340 • ACR Convergence 2020
Secukinumab Improves Pain, Morning Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients with Non-Radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study
Helena Marzo-Ortega¹, Atul Deodhar², Ricardo Blanco³, Hideto Kameda⁴, Alan Kivitz⁵, Denis Poddubnyy⁶, Marina Magrey⁷, Jianyuan Wang⁸, Sibylle Haemmerle⁸, Abhijit Shete⁸ and Juergen Braun⁹, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²Oregon Health & Science University, Portland, OR, ³Hospital University Marqués de Valdecilla, Santander, Spain, ⁴Toho University, Tokyo, Japan, ⁵Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁷Case Western Reserve University School of Medicine, Cleveland, OH, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Rheumazentrum Ruhrgebiet and Ruhr-University, 44649 Herne, Germany
Background/Purpose: Patients with non-radiographic axial spondyloarthritis (nr-axSpA) suffer from comparable disease burden to patients with ankylosing spondylitis/radiographic axSpA (AS/r-axSpA), including inflammatory back pain, morning stiffness,…
Abstract Number: 1341 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
Vibeke Strand¹, Philip Mease², Enrique Soriano³, Mitsumasa Kishimoto⁴, Carlo Salvarani⁵, Nemanja Damjanov⁶, Jaclyn K Anderson⁷, Erin Blondell⁷, Patrick Zueger⁷, Christopher Saffore⁷ and Dafna Gladman⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina, ⁴Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ⁵Rheumatology Units, University of Modena and Reggio Emilia, and Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy, ⁶University of Belgrade Medical School, Belgrade, Serbia, ⁷AbbVie Inc., North Chicago, IL, ⁸Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in PsA. We present an analysis of PRO data from the SELECT-PsA 1 study.Methods: SELECT-PsA…
Abstract Number: 1342 • ACR Convergence 2020
Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK
Filip Van den Bosch¹, Peter Nash², James Cheng-Chung Wei³, Francisco Blanco⁴, Vassilis Tsekouras⁵, Chuanbo Zang⁶, Daniela Graham⁷, Edmund Arthur⁸, Pamela Selema⁶, Bonnie Vlahos⁶ and Atul Deodhar⁹, ¹Ghent University Hospital, Ghent, Belgium, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ⁴INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruna, Spain, ⁵Pfizer, Nicosia, Cyprus, ⁶Pfizer, Collegeville, PA, ⁷Pfizer, Groton, PA, ⁸Pfizer, Peapack, NJ, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Etanercept (ETN) is effective and well tolerated in patients with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is limited information on the effects of withdrawing…
Abstract Number: 1343 • ACR Convergence 2020
Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
Philip Mease¹, Pamela Young², David Gruben³, Lara Fallon⁴, Rebecca Germino⁵ and Arthur Kavanaugh⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Montreal, QC, Canada, ⁵Pfizer Inc, New York, NY, ⁶UC San Diego Health System, San Diego, CA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). It was approved in the US in December 2017 for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].